1. How to Choose the Right CDMO
2. A Success Story on Partnership: The Invisible Superpower in CDMO Projects
3. Trends and Requirements in CDMO Projects for Biopharmaceuticals
4. Investing in Efficiency: Benefits of Process Intensification in Upstream Processing
5. Transposons and Transposases: A Dynamic Duo in Genetic Advancements
For us and our partners, 2025 has been a year defined by scientific progress, collaboration, and a shared commitment to advancing how biopharmaceuticals are developed and manufactured. In discussions with partners, one sentiment stood out: the journey from early concept to GMP reality is becoming more interconnected than ever—and choosing the right strategies, tailored to their molecule, makes all the difference.
Our blog readers gravitated toward content that offered exactly that kind of orientation. Practical insights, clear explanations, and frameworks that help navigate an increasingly sophisticated development and manufacturing landscape.
Here are the five articles from our side that captured the most interest in 2025—each reflecting the questions, challenges, and opportunities that shaped the year for our community and show where 2026 is heading.
Choosing a CDMO is rarely a straightforward decision. Projects differ, molecules behave unpredictably, and different partners bring very different strengths to the table. This article highlights the criteria that truly matter in practice—from process development expertise and analytical depth to platform robustness and the ability to adapt when projects take unexpected turns.
How to Choose the Right CDMO Partner for Your Project
This blog sheds light on an often underestimated factor in CDMO–client collaborations: seamless communication and cross-functional integration. As timelines tighten and molecule complexity rises, collaboration quality is becoming just as important as technical expertise.
A Success Story on Partnership - the Invisible Superpower in CDMO Projects
Biopharma programs today require increasing alignment across development, regulatory strategy, and manufacturing. This article summarizes what biopharma companies look for in a CDMO and how project needs are evolving from Phase 1 through commercial readiness.
As companies seek faster, more robust clinical manufacturing, process intensification has become an essential tool. This article explores how intensified Fed-Batch and perfusion strategies can reduce timelines, increase productivity, and build greater flexibility into development pipelines.
Investing in Efficiency: Benefits of Process Intensification in Upstream Processing
The development of stable, high-expressing cell lines is essential for the production of modern biologics, including bispecifics and advanced gene therapy vectors. Transposon-based systems are increasingly adopted as efficient tools to achieve these goals.
Transposons and Transposases: A Dynamic Duo in Genetic Engineering
As your trusted partner, we focus on what matters most: people, science, and making innovation work. Our mission goes beyond technical excellence. It is about understanding each project’s unique challenges and delivering results that truly matter.
In 2026, we will continue sharing practical insights, lessons from the lab, and perspectives shaped by real collaboration, helping bring better therapies to patients faster and with lasting impact.
Explore all articles in our library for more insights, stories, and perspectives from the ProBioGen team.